Regeneron to Lead $50M Exome Sequencing Consortium with UK Biobank

Regeneron Pharmaceticals said today the $50 million-plus consortium it has launched with five biopharmas will reshape drug development and even human health beyond simply speeding up exome sequencing of all 500,000 people within the UK Biobank by three years, to 2019.AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen, and Pfizer have agreed to invest $10 million each to join the Regeneron-led precompetitive sequencing project. The five may be joined by additional biopharma partners that have e